Cytosorbents Total Long Term Liabilities 2010-2024 | CTSO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cytosorbents total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cytosorbents total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$199.9B
Stryker (SYK)	$137.7B
Boston Scientific (BSX)	$121.6B
Medtronic (MDT)	$113B
EssilorLuxottica (ESLOY)	$104.4B
Haleon (HLN)	$48.1B
Lonza Group Ag (LZAGY)	$45.4B
ResMed (RMD)	$35B
Koninklijke Philips (PHG)	$29B
Terumo (TRUMY)	$27.9B
Zimmer Biomet Holdings (ZBH)	$21.6B
Baxter (BAX)	$20.1B
Insulet (PODD)	$16.6B
Smith & Nephew SNATS (SNN)	$13.4B
Bio-Rad Laboratories (BIO)	$9.5B
Demant (WILYY)	$9.2B
BellRing Brands (BRBR)	$7.7B
Lantheus Holdings (LNTH)	$7.5B
ICU Medical (ICUI)	$4.3B
TG Therapeutics (TGTX)	$3.9B
Haemonetics (HAE)	$3.9B
Perrigo (PRGO)	$3.8B
GN Store Nord (GNNDY)	$3.8B
Neogen (NEOG)	$3.7B
Prestige Consumer Healthcare (PBH)	$3.6B
Envista Holdings (NVST)	$3.3B
QuidelOrtho (QDEL)	$3.1B
Agios Pharmaceuticals (AGIO)	$2.6B
Maravai LifeSciences Holdings (MRVI)	$2.3B
Green Thumb Industries (GTBIF)	$2.2B